Resources Repository
-
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Test Performance | Technology Assessment | Cost-Effectiveness Analysis | Costing Methods | North America | Policy/Regulation | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | North America | Policy/Regulation | Chronic Disease/Risk | Infectious Diseases | Child/Nutrition | Health Systems | Economics/Finance | Government/Law | Health/Medicine -
ReviewWeb Portal 2016Use of Economics in Informing U.S. Public Health Policy
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics …
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics in Informing U.S. Public Health Policy” is to influence policy researchers to identify and undertake economic research that generates the key evidence needed to inform policy. In public health, economic evaluation, primarily cost and cost-effectiveness analysis, has been widely used to demonstrate the economic burden of health-related conditions and the value of proposed programs and policies. However, despite the wealth…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Costing Methods | North America | Policy/Regulation | Health Outcomes | Health Systems | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Costing Methods | North America | Policy/Regulation | Preferences/Values | Social Determinants | Environmental Health | Health Systems | Climate/Environment | Economics/Finance | Food/Agriculture | Health/Medicine -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Priority Setting/Ethics | Technology Assessment | North America | Policy/Regulation | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine -
DataWeb Portal 2024Medical Expenditure Panel Survey (MEPS)
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring …
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring how Americans use and pay for medical care, health insurance, and out-of-pocket spending. Annual surveys of individuals and families, as well as their health care providers, provide data on health status, the use of medical services, charges, insurance coverage, and satisfaction with care. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form…
Cost-Effectiveness Analysis | Costing Methods | North America | Policy/Regulation | Health Outcomes | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine -
ReviewWeb Portal 2015Science of Making Better Decisions About Health: CEA and BCA
This chapter reviews the main scientific methods for guiding the allocation of resources to health: cost-effectiveness …
This chapter reviews the main scientific methods for guiding the allocation of resources to health: cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA), sketches their methodological progress over the last several decades, and presents examples of how medical practice in other high-income countries, where people live longer, follows the priorities indicated by cost-effectiveness analysis.
Benefit-Cost Analysis | Cost-Effectiveness Analysis | North America | Policy/Regulation | Health Systems | Health/Medicine -
Working PaperPublication 2015Benefit-Cost Analysis and the Cities
This paper provides a short introduction to the use of benefit-cost analysis to assess interventions …
This paper provides a short introduction to the use of benefit-cost analysis to assess interventions undertaken at the city or municipal level. It introduces the concepts that underlie the conduct of benefit-cost analysis, describes the major analytic components, and discusses how to tailor the analysis to the characteristics of the policy and the resources available. It concludes with a list of references for those interested in learning more.
Priority Setting/Ethics | Benefit-Cost Analysis | North America | Policy/Regulation | Preferences/Values | Decision Analysis | Social Determinants | Environmental Health | Climate/Environment | Culture/Society | Economics/Finance | Government/Law | Critical Thinking/Analysis -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Health/Medicine